Fisher Asset Management
IHE icon

Fisher Asset Management’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Fisher Asset Management’s Portfolio IHE Stock Details IHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$240M Sell
2,767,359
-58,285
-2% -$5.1M 0.08% 124
2025
Q4 		$240M Sell
2,825,644
-60,698
-2% -$4.84M 0.08% 123
2025
Q3 		$209M Sell
2,886,342
-90,349
-3% -$6.23M 0.08% 130
2025
Q2 		$195M Sell
2,976,691
-166,258
-5% -$10.8M 0.08% 132
2025
Q1 		$222M Sell
3,142,949
-83,745
-3% -$5.82M 0.1% 121
2024
Q4 		$212M Sell
3,226,694
-125,550
-4% -$8.64M 0.08% 122
2024
Q3 		$237M Sell
3,352,244
-88,758
-3% -$6.18M 0.1% 121
2024
Q2 		$228M Sell
3,441,002
-94,857
-3% -$6.22M 0.1% 119
2024
Q1 		$240M Sell
3,535,859
-85,180
-2% -$5.63M 0.11% 118
2023
Q4 		$224M Buy
3,621,039
+3,557,088
+5,562% +$209M 0.12% 124
2023
Q3 		$3.77M Sell
63,951
-60,870
-49% -$3.73M ﹤0.01% 551
2023
Q2 		$7.45M Buy
124,821
+9,093
+8% +$541K ﹤0.01% 488
2023
Q1 		$6.76M Sell
115,728
-447
-0.4% -$26.9K ﹤0.01% 502
2022
Q4 		$7.21M Buy
116,175
+50,625
+77% +$3.05M ﹤0.01% 497
2022
Q3 		$3.71M Buy
65,550
+40,302
+160% +$2.48M ﹤0.01% 492
2022
Q2 		$1.61M Sell
25,248
-870
-3% -$55.2K ﹤0.01% 561
2022
Q1 		$1.69M Sell
26,118
-14,055
-35% -$891K ﹤0.01% 574
2021
Q4 		$2.67M Buy
40,173
+16,935
+73% +$1.07M ﹤0.01% 527
2021
Q3 		$1.42M Buy
23,238
+1,395
+6% +$88.7K ﹤0.01% 565
2021
Q2 		$1.35M Sell
21,843
-4,365
-17% -$265K ﹤0.01% 572
2021
Q1 		$1.55M Sell
26,208
-1,641
-6% -$99K ﹤0.01% 557
2020
Q4 		$1.67M Buy
27,849
+12,453
+81% +$710K ﹤0.01% 540
2020
Q3 		$839K Sell
15,396
-1,425
-8% -$76.9K ﹤0.01% 583
2020
Q2 		$863K Sell
16,821
-19,413
-54% -$976K ﹤0.01% 586
2020
Q1 		$1.63M Sell
36,234
-107,139
-75% -$5.4M ﹤0.01% 475
2019
Q4 		$7.65M Buy
143,373
+130,680
+1,030% +$6.44M 0.01% 362
2019
Q3 		$592K Buy
12,693
+4,632
+57% +$222K ﹤0.01% 663
2019
Q2 		$405K Buy
+8,061
New +$398K ﹤0.01% 696

Other funds holding IHE

FIA
Foundations Investment Advisors Phoenix, Arizona $8.07B AUM 24.97% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACA
Aptus Capital Advisors Fairhope, Alabama $12.7B AUM 17.41% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $403M AUM 28.73% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return
IWS
Insight Wealth Strategies San Ramon, California $1.02B AUM 38% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fisher Asset Management's IHE Position: Q1 2026 in Review

Fisher Asset Management reduced its iShares US Pharmaceuticals ETF (IHE) stake by 2.1% in Q1 2026, selling an estimated $5.1M and leaving 2,767,359 shares worth $240M. The position accounts for 0.08% of the portfolio, ranked #124.

Fisher Asset Management first reported a position in IHE in Q2 2019 and has held it in 28 quarters since. The position peaked at $240M in Q1 2024. 194 funds tracked by Wall St. Rank hold IHE as of Q1 2026.

  • Fisher Asset Management held 2,767,359 shares of iShares US Pharmaceuticals ETF worth $240M as of Q1 2026.
  • Fisher Asset Management sold 58,285 iShares US Pharmaceuticals ETF shares in Q1 2026, an estimated $5.1M.
  • iShares US Pharmaceuticals ETF made up 0.08% of Fisher Asset Management's portfolio in Q1 2026, its #124 holding.
  • Fisher Asset Management first reported a position in iShares US Pharmaceuticals ETF in Q2 2019 and has held it in 28 quarters since.
  • Fisher Asset Management's iShares US Pharmaceuticals ETF position peaked at $240M in Q1 2024.
  • 194 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q1 2026.

Based on Fisher Asset Management's 13F filing for Q1 2026, filed 5 May 2026.